Related Experiment Video
Updated: May 16, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Non-immune targeting of CXCR3 compromises mitochondrial function and suppresses tumor growth in glioblastoma
Travis Yui Hei Chan1, Bo Chen1, Wanjun Tang1
1Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Abstract:
The chemokine receptor CXCR3 is traditionally recognized for its role in immune cell trafficking. However, emerging evidence suggests that its functions may extend beyond the immune system, particularly in cancer, where its roles remain to be elucidated. In this study, we demonstrated that CXCR3 expression correlates with glioblastoma (GBM) grading, with CXCR3-A isoform being associated with poorer patient prognosis compared to CXCR3-B. Ablation of both CXCR3 isoforms significantly impaired GBM cell proliferation, migration, and tumor growth both in vitro and in immunodeficient mice. To elucidate the mechanistic role of CXCR3, we conducted transcriptomic profiling of tumor xenografts, revealing that CXCR3 depletion would disrupt mitochondrial homeostasis. This was further supported by our findings that CXCR3 would localize to the mitochondrial membrane, and that inhibition of CXCR3 would lead to mitochondrial depolarization and increased reactive oxygen species production. Notably, activation of phosphorylated-STAT3 rescued cell viability in CXCR3-depleted cells, suggesting that CXCR3 may modulate mitochondrial function through a STAT3-dependent mechanism, consistent with the known functional role of STAT3 in maintaining mitochondrial redox balance. Furthermore, treatment with the selective CXCR3 antagonist AMG487 reduced tumor growth and disrupted mitochondrial function in vitro, in vivo, and in patient-derived GBM stem cells. Our findings reveal CXCR3 as a previously unrecognized regulator of mitochondrial function in cancer cells, positioning the CXCR3-mitochondrial signaling axis as a promising therapeutic target for GBM. Chemokine receptors are well-established mediators of inflammatory responses, emerging evidence suggests that these receptors may play roles beyond the immune system. In this study, we have demonstrated that CXCR3 would localize to the mitochondrial membrane and exert a previously unrecognized function in regulating cancer metabolism and mitochondrial function. Figure created using BioRender ( https://biorender.com ).
Insights
The chemokine receptor CXCR3 regulates mitochondrial function in glioblastoma (GBM) cells, impacting cancer growth. Targeting this CXCR3-mitochondrial axis offers a new therapeutic strategy for GBM.
Area of Science:
- Oncology
- Cell Biology
- Molecular Medicine
Background:
- Chemokine receptors, like CXCR3, are known for immune cell roles.
- Emerging research suggests non-immune functions, particularly in cancer.
- The specific roles of CXCR3 in glioblastoma (GBM) require further elucidation.
Purpose of the Study:
- To investigate the non-immune functions of CXCR3 in glioblastoma.
- To determine the correlation between CXCR3 expression and GBM patient prognosis.
- To elucidate the mechanism by which CXCR3 influences GBM cell behavior and tumor growth.
Main Methods:
- Analysis of CXCR3 expression in relation to GBM grading and patient prognosis.
- In vitro and in vivo experiments involving CXCR3 isoform ablation in GBM cells.
- Transcriptomic profiling of tumor xenografts to identify molecular pathways affected by CXCR3.
- Mitochondrial function assays, including membrane potential and reactive oxygen species production.
- In vivo studies using the CXCR3 antagonist AMG487.
Main Results:
- CXCR3 expression correlates with GBM grade, with CXCR3-A linked to poorer prognosis.
- CXCR3 ablation impairs GBM cell proliferation, migration, and tumor growth.
- CXCR3 localizes to the mitochondrial membrane, regulating mitochondrial homeostasis.
- CXCR3 inhibition disrupts mitochondrial function, leading to depolarization and increased ROS.
- STAT3 activation rescues viability in CXCR3-depleted cells, suggesting a STAT3-dependent mechanism.
- AMG487 treatment reduces tumor growth and impairs mitochondrial function in GBM models.
Conclusions:
- CXCR3 is a novel regulator of mitochondrial function in cancer cells.
- The CXCR3-mitochondrial signaling axis represents a potential therapeutic target for GBM.
- Targeting CXCR3 may offer a new strategy to combat glioblastoma growth and progression.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...

